EGFR and non-small cell lung carcinoma: The therapeutic strategy to use for EGFR-mutant advanced NSCLC patients progressed to first-line EGFR-TKI may use NGS analysis to detect early signals of drug resistance, to potentially direct the switching to an alternative antitumor drug or combination to overcome relevant subclonal progression.